Skip to content
Screener

Celldex Therapeutics CLDX Business Segments — Labor And Related Expense

Similar metrics at other companies

Capricor Therapeutics logo
CAPRSingle Reportable — Labor And Related Expense
$2.23M+48.9%
LQD
LQDASingle Reportable — Labor And Related Expense
$31.65M+57.6%
Citi Trends logo
CTRNSingle Reportable — Labor And Related Expense
$23.91M+6.3%
UroGen Pharma logo
URGNSingle Reportable — Labor And Related Expense
$25.38M+29.7%
Scholar Rock logo
SRRKSingle Reportable — Labor And Related Expense
$37.45M+15.3%
Cracker Barrel Old Country Store logo
CBRLSingle Reportable — Labor And Related Expense
$302.08M-0.9%

Other financials

Income statement

See full
Revenue$22.0K-97.0%
Operating income-$80.6M-26.3%
Net income-$73.5M-29.9%
EPS (diluted)-$0.94-10.6%

Balance sheet

See full
Cash & equivalents$47.5M+106%
Total debt$4.9M+61.8%
Total equity$714.6M+9.0%
Total assets$782.3M+13.0%

Cash flow

See full
Operating cash flow-$57.4M-30.5%
CapEx$3.2M+337%
Free cash flow-$60.6M-35.4%

Valuation

See full
Market cap$3.26B+129%
Enterprise value$3.22B+129%
P/S20,646.4×+20,401×

Profitability

See full
Operating margin-206,220.3%-210,440pp
Net margin-190,220.9%-193,797pp
FCF margin-153,231%-156,630pp

Returns & leverage

See full
Return on equity-43.9%+70.0pp
Debt / equity0.0×
Current ratio11.8×-7.8×

Where this comes from

Reported directly by Celldex Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:LaborAndRelatedExpense.

The source filing: Celldex Therapeutics’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:06 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001104659-26-091984
Line itemThree Months Ended / June 30, 2026Three Months Ended / June 30, 2025Six Months Ended / June 30, 2026Six Months Ended / June 30, 2025
Personnel$15,885$14,129$31,454$27,729
Laboratory supplies2,5931,5444,0513,712
Facility1,1781,3982,1182,803
Product development (b)41,74633,53691,90365,702
Other expenses (c)6,1403,58911,0176,864
Total R&D expense$67,542$54,196$140,543$106,810

Item 1. Unaudited Financial Statements

FAQ

What is Celldex Therapeutics's business segments — labor and related expense?
Celldex Therapeutics (CLDX) reported business segments — labor and related expense of $15.89M in Q2 2026.
How has Celldex Therapeutics's business segments — labor and related expense changed year-over-year?
Celldex Therapeutics's business segments — labor and related expense increased by 12.4% year-over-year, from $14.13M to $15.89M.
What does business segments — labor and related expense mean?
This metric captures the total compensation and benefits costs associated with the workforce dedicated to the company's primary business segment. It reflects the investment in human capital required to drive research, development, and operational objectives. Analyzing this expense helps investors understand the company's labor intensity and its ability to attract and retain specialized scientific talent.

Ask your AI about Celldex Therapeutics's business segments — labor and related expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude